---
title: COPD (INICET High-Yield)
markmap:
  colorFreezeLevel: 6
---

## COPD
- ### Definition & Diagnosis
  - Persistent respiratory symptoms
  - Airflow limitation (not fully reversible)
  - **Spirometry:**
    - Post-bronchodilator FEV1/FVC < 0.70 (Diagnostic hallmark)
    - FEV1 severity grading (GOLD 1-4)
- ### Pathophysiology
  - **Chronic Bronchitis:**
    - Mucus hypersecretion
    - Airway inflammation & remodeling
    - Cough > 3 months in 2 successive years
  - **Emphysema:**
    - Destruction of lung parenchyma (alveolar walls)
    - Enlarged air spaces
    - Loss of elastic recoil
- ### Risk Factors
  - **Smoking** (Primary)
  - Occupational dusts/chemicals
  - Air pollution (indoor/outdoor)
  - Alpha-1 Antitrypsin Deficiency (Genetic, panlobular emphysema, younger age)
  - History of TB
- ### Clinical Presentation
  - **Symptoms:**
    - Dyspnea (progressive, persistent)
    - Chronic cough (intermittent/productive)
    - Sputum production
    - Wheezing
  - **Signs:**
    - Barrel chest (Emphysema)
    - Cyanosis, Peripheral edema ("Blue Bloaters" - Bronchitis dominant)
    - Pursed-lip breathing, Cachexia ("Pink Puffers" - Emphysema dominant)
    - Use of accessory muscles
    - Reduced breath sounds, Rhonchi, Wheeze
- ### Classification & Severity (GOLD)
  - **Based on FEV1 (Post-bronchodilator):**
    - GOLD 1 (Mild): FEV1 ≥ 80% predicted
    - GOLD 2 (Moderate): 50% ≤ FEV1 < 80% predicted
    - GOLD 3 (Severe): 30% ≤ FEV1 < 50% predicted
    - GOLD 4 (Very Severe): FEV1 < 30% predicted
  - **Based on Symptoms & Exacerbation History:**
    - Groups A, B, C, D (CAT score, mMRC dyspnea scale, Exacerbation frequency)
- ### Management (Stable COPD)
  - **Pharmacological:**
    - **Bronchodilators:**
      - SABA (Salbutamol) - Rescue
      - LABA (Salmeterol, Formoterol)
      - SAMA (Ipratropium) - Rescue
      - LAMA (Tiotropium, Umeclidinium) - Cornerstone
      - Combination (LABA+LAMA, LABA+ICS)
    - **Inhaled Corticosteroids (ICS):**
      - Added for severe symptoms or frequent exacerbations (GOLD C/D or blood eosinophils)
      - Risk of pneumonia
    - Phosphodiesterase-4 Inhibitor (Roflumilast) - Severe COPD, chronic bronchitis phenotype
    - Oral Steroids (Avoid long-term)
  - **Non-Pharmacological:**
    - **Smoking Cessation** (Most important intervention)
    - **Pulmonary Rehabilitation** (Improves exercise tolerance, QoL)
    - **Oxygen Therapy:**
      - Indicated for chronic hypoxemia (PaO2 ≤ 55 mmHg or ≤ 60 mmHg with Cor Pulmonale/Polycythemia)
      - >15 hrs/day prolongs survival
    - **Vaccinations:**
      - Influenza (Annually)
      - Pneumococcal (PCV13 followed by PPSV23)
    - Nutritional support
    - Surgical (Lung volume reduction surgery, Transplant - selected cases)
- ### Acute Exacerbations
  - **Definition:** Acute worsening of respiratory symptoms requiring change in usual medication.
  - **Causes:** Viral/Bacterial infections (most common), Pollutants.
  - **Management:**
    - Supplemental Oxygen (Target SpO2 88-92%)
    - Increased dose/frequency of Bronchodilators (SABA/SAMA)
    - Systemic Corticosteroids (Oral/IV - 5-7 days)
    - Antibiotics (If signs of bacterial infection: increased sputum purulence, volume, dyspnea)
    - Non-invasive Ventilation (NIV) - Acute respiratory failure, acidosis
    - Hospitalization criteria (severe symptoms, high risk, failure of outpatient Rx)
- ### Complications
  - Cor Pulmonale (RV hypertrophy/failure due to pulmonary hypertension)
  - Respiratory Failure (Acute or Chronic)
  - Secondary Polycythemia
  - Weight loss/Cachexia
  - Depression/Anxiety
  - Osteoporosis
- ### INICET Buzzwords
  - FEV1/FVC < 0.70 (Post-bronchodilator)
  - GOLD Staging (1, 2, 3, 4)
  - GOLD Grouping (A, B, C, D)
  - CAT score / mMRC scale
  - Smoking Cessation
  - Pulmonary Rehabilitation
  - Long-term Oxygen Therapy (>15 hrs/day)
  - LAMA (Tiotropium)
  - LABA/LAMA Combination
  - ICS indication (Eosinophils, Exacerbations)
  - Roflumilast
  - Cor Pulmonale
  - Acute Exacerbation Management (Steroids, Antibiotics, NIV)
  - Alpha-1 Antitrypsin Deficiency


